Navigation Links
Chimerix to Present at the Citi 2011 Global Health Care Conference
Date:2/24/2011

DURHAM, N.C., Feb. 24, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the Citi 2011 Global Health Care Conference on March 1, 2011 at 3:00 p.m. ET at the Hilton New York Hotel in New York City, NY.

Mr. Moch will give an update on the company's pipeline and technology assets, including CMX001, a broad-spectrum antiviral being developed for the treatment of a wide range of infections caused by double-stranded DNA (dsDNA) viruses.  CMX001 is in Phase 2 clinical studies in immunocompromised transplant and cancer patients for the prophylaxis and/or pre-emption of dsDNA viruses such as cytomegalovirus and adenovirus, as well as an Open-Label Study for the treatment of patients with any of 12 different dsDNA infections that is designed to provide supportive data for CMX001's pivotal studies.  CMX001 is also being developed as a potential medical countermeasure in the event of a smallpox release.

About Chimerix and CMX001

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  

The company's lead candidate, CMX001, is being developed as a potential broadspectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases.  Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.  

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transp
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
2. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
3. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
4. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
5. Chimerix to Present at 9th Annual BIO Investor Forum
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
8. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
9. Chimerix to Present at Two Upcoming Investor Conferences
10. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
11. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Ohio , Aug. 28, 2014  A ... competition in generics are adding pressure to pharmaceutical, ... resources. Company resources continue to shrink and approval ... This has led companies to look for additional ... commercialization and for keeping approved products on the ...
(Date:8/28/2014)... VIEJO , Kalifornien, 28. August ... hat heute den Start der Patientenrekrutierung ... Device Exemption, Forschungsausnahmegenehmigung) zur Beurteilung der ... zur Embolisation von Aneurysmen („WEB") bekanntgegeben. Adam ... of Tennessee, Department of Neurosurgery/Semmes-Murphey Clinic, ...
(Date:8/28/2014)... , Aug. 28, 2014  Sequent Medical, ... enrollment in an Investigational Device Exemption ("IDE") pivotal ... the WEB™ Aneurysm Embolization System ("WEB"). Adam ... Department of Neurosurgery/Semmes-Murphey Clinic and Principal Investigator of ... the study, treating them with the WEB at ...
Breaking Medicine Technology:4 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3
... Medical International Limited (NYSE: MR ), a leading ... its selected unaudited financial results for the first quarter ended ... First Quarter 2011 Net revenues were $180.9 ... 2010. Robust international sales of $108.5 million, a year-over-year ...
... /PRNewswire-Asia/ -- Chindex International, Inc. (NASDAQ: ... services in China through the operations of United Family Healthcare, ... clinics, today announced financial results for the three month period ... 2011 Financial Highlights Revenue from healthcare ...
Cached Medicine Technology:Mindray Announces First Quarter 2011 Financial Results 2Mindray Announces First Quarter 2011 Financial Results 3Mindray Announces First Quarter 2011 Financial Results 4Mindray Announces First Quarter 2011 Financial Results 5Mindray Announces First Quarter 2011 Financial Results 6Mindray Announces First Quarter 2011 Financial Results 7Mindray Announces First Quarter 2011 Financial Results 8Mindray Announces First Quarter 2011 Financial Results 9Mindray Announces First Quarter 2011 Financial Results 10Mindray Announces First Quarter 2011 Financial Results 11Mindray Announces First Quarter 2011 Financial Results 12Mindray Announces First Quarter 2011 Financial Results 13Mindray Announces First Quarter 2011 Financial Results 14Chindex International, Inc. Reports First Quarter 2011 Financial Results 2Chindex International, Inc. Reports First Quarter 2011 Financial Results 3Chindex International, Inc. Reports First Quarter 2011 Financial Results 4Chindex International, Inc. Reports First Quarter 2011 Financial Results 5Chindex International, Inc. Reports First Quarter 2011 Financial Results 6Chindex International, Inc. Reports First Quarter 2011 Financial Results 7Chindex International, Inc. Reports First Quarter 2011 Financial Results 8Chindex International, Inc. Reports First Quarter 2011 Financial Results 9Chindex International, Inc. Reports First Quarter 2011 Financial Results 10
(Date:8/28/2014)... 28, 2014 AmeriPride Services, a leading ... announced the launch of its new Customer Portal, an ... easier and more convenient for customers. The industry-leading digital ... better communicate with the company. , Features of the ... Access, download and pay bills online , ...
(Date:8/28/2014)... 2014 Clarity PSO , an ... as a federal Patient Safety Organization (PSO) for another ... Healthcare Research and Quality (AHRQ). Clarity PSO will continue ... services following the true intentions of the Patient Safety ... are proud and eager to continue our journey as ...
(Date:8/28/2014)... 2014 Genetic testing for multiple ... world, with large reference laboratories as well as ... with regard to the genetic variants analyzed, the ... struggle to find the most appropriate laboratory providers ... sort through these differences, Hayes, Inc. has added ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 veEDIS ... Emergency Department Information System (EDIS), in Lawrence Medical ... nurses and physicians to document patient care, veEDIS ... patient record-keeping, as well as the authorized, confidential ... Through the veEDIS technology, designed in accordance ...
(Date:8/28/2014)... Altec Products, Inc., a leader ... today that they have been awarded the “Partnering ... the International Association of Microsoft Channel Partners (IAMCP) ... in 1994, providing Microsoft Partners with a voice ... at large while facilitating mutual growth and business ...
Breaking Medicine News(10 mins):Health News:AmeriPride Services Launches New Customer Portal 2Health News:AmeriPride Services Launches New Customer Portal 3Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 3Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 2Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 3Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 2Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 3
... of patients whose myelodysplastic syndrome is related to earlier ... have a poor prognosis, researchers from The University of ... Annual Meeting of the American Society of Hematology. ... or both treatments are usually told that they have ...
... of biological macromolecules are the central bases of ... cells by linking many small molecules together. Naturally ... A detailed understanding of the synthesis of these ... for understanding biological systems, and for the development ...
... smells apart is no problem for the human nose. How ... by an interdisciplinary team of researchers at the RUB. The ... of the three-dimensional structure of the binding site of an ... pattern of hydrogen bonds between odorant and receptor, which accounts ...
... News) -- Undiagnosed chronic fatigue syndrome may account for up ... for extended periods of time and are not truant or ... out of school, a new study reveals. For the ... 16 at three secondary schools in England and concluded that ...
... US Prostate Cancer Prevention Trial found cancer in many men ... which PSA level should lead to a biopsy recommendation. ... considerable controversy, that the evidence does not support recommending PSA ... the risks outweigh the benefits. Now, a study shows ...
... - Adding a drug that activates genes to frontline combination ... remission rate after initial treatment, researchers at The University of ... Meeting of the American Society of Hematology. Results of ... stage for a national Phase III clinical trial of the ...
Cached Medicine News:Health News:Prognostic model developed for MDS related to prior cancer therapy 2Health News:Prognostic model developed for MDS related to prior cancer therapy 3Health News:Visualization of DNA synthesis in vivo 2Health News:A good nose: RUB-Researchers decipher interaction of fragrances and olfactory receptors 2Health News:Chronic Fatigue Tied to Extended School Absences 2Health News:Biopsy referral after PSA screening stays consistent over time 2Health News:AML patients have high response rate with vorinostat added to treatment 2
HbA1c / HbCalibrator...
Heparin-Platelet Factor 4 Induced Antibody...
Multi-constituent Calibration Plasma for Functional Assays of Coagulation Parameters on STA© Analyzers....
Control Plasma for Assays of Unfractionated Heparins (UH) using Anti-Xa Methodon STA© Analyzers....
Medicine Products: